Inhibitori imunoloških kontrolnih točaka su klasa lijekova koji se bore s imunološkim sustavom tijela u borbi protiv stanica raka. Međutim, većina pacijenata ne reagira na te terapije. Postoji novija klasa lijekova koja cilja dva proteina uključena u suzbijanje imunološkog odgovora tijela protiv tumora.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from Raka with the molecule M7824. These researchers are also undertaking trials with those suffering from karcinom gušterače and those infected with HPV.
There are many other trials and experiments being taken to treat and izliječiti rak more effectively in different research institutes. This drug with a dual approach will be a boon in the liječenje raka, as with a single molecule, multiple therapies are included.
